Pharmacogenomics-Guided Dalcetrapib Therapy after an Acute Coronary Syndrome (dal-GenE)

The dal-GenE trial randomized 6,147 post-ACS patients to dalcetrapib (a CETP inhibitor that raises HDL-C) or placebo, with patient selection enriched for the AA genotype of the ADCY9 gene — which was identified from earlier pharmacogenomic analyses as a predictor of benefit from dalcetrapib therapy.

Among genotypically selected patients (ADCY9 AA genotype), dalcetrapib showed a numerically favorable but statistically non-significant trend toward cardiovascular event reduction (HR 0.84, 95% CI 0.70–1.02, p=0.076). The study was powered to detect a larger treatment effect than was observed. In the primary pre-specified endpoint, the trial did not achieve statistical significance.

The trial’s design is notable as one of the first large cardiovascular outcome trials to prospectively use pharmacogenomic selection to enrich for likely responders — motivated by the recognition that earlier dalcetrapib trials in unselected populations showed no benefit. The ADCY9 genotype’s role in mediating dalcetrapib response involves adenylyl cyclase 9’s modulation of downstream inflammatory pathways, not HDL metabolism per se.

The broader lesson from CETP inhibitor trials (torcetrapib, dalcetrapib, evacetrapib, anacetrapib) is that raising HDL-C as a primary mechanism does not reliably reduce cardiovascular events — HDL function and particle biology matter more than HDL-C concentration alone. Anacetrapib was the lone CETP inhibitor to show significant event reduction, and its effect was attributed primarily to LDL-lowering rather than HDL-raising.

We rate the evidence moderate. A pharmacogenomics-guided RCT in 6,147 patients showing a non-significant trend toward cardiovascular benefit from dalcetrapib in genetically selected patients — a technically sophisticated trial that underscores the difficulty of precision-medicine–guided drug development in cardiovascular disease.